Extracellular Vesicle RNA Analysis for Glioma Progression Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring gliomas, particularly distinguishing between pseudo-progression and true-progression, are invasive, unreliable, and lack real-time monitoring capabilities, leading to delayed and inaccurate treatment decisions.
Innovation Solution
A method involving the preparation of an RNA sequence library from extracellular vesicles using capture and amplification by tailing and switching (CATS), followed by analysis with a k-mers based machine learning algorithm, to detect and classify tumors, cysts, lesions, or cancers, and monitor their progression or recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiologic assessment and tissue biopsy are used for diagnosing gliomas, then diagnostic capability is achieved, but the method is invasive and has limited utility depending on tumor location and tissue heterogeneity
Solution Approach 1:
The patent extracts and analyzes RNA molecules from circulating tumor cells and extracellular vesicles in blood samples, eliminating the need for invasive tissue biopsy. This allows diagnostic information to be obtained from easily accessible blood samples while maintaining diagnostic reliability through analysis of tumor-specific RNA markers.
Solution Approach 2:
The patent uses RNA molecules in blood samples as intermediary markers that carry diagnostic information about the tumor without requiring direct access to the tumor tissue. These RNA intermediaries (including retroelements and transposable elements) serve as proxies for tumor presence and characteristics, enabling non-invasive diagnosis.
2Reliability
If serial imaging is used to monitor tumor progression, then monitoring capability is achieved, but diagnosis and management decisions are delayed by several weeks
Solution Approach 1:
The patent performs preliminary analysis of RNA markers in blood samples that can detect tumor progression before it becomes visible on serial imaging. By monitoring RNA biomarkers continuously in accessible blood samples, the system provides early warning of tumor changes, enabling timely intervention before the several-week delay inherent in waiting for imaging results.
3Measurement precision
If qualitative and quantitative MRI-based approaches are used to differentiate pseudo-progression from true-progression, then differentiation capability is attempted, but the delineation remains extremely challenging
Solution Approach 1:
The patent replaces complex MRI-based mechanical and visual assessment methods with a molecular biology approach using RNA analysis. Instead of relying on radiologists to interpret complex imaging patterns, the system uses specific RNA markers (including retroelements and transposable elements) that provide direct molecular evidence of tumor progression, simplifying the diagnostic process while improving precision.
Data Source
AI summary
The present disclosure is directed to methods for determining the presence, type, or grade of a tumor, cyst, lesion, mass and/or cancer, or classifying or subtyping a tumor, cyst, lesion, mass, and/or cancer, in a sample obtained from a subject.